Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study

Andres Acosta, Michael Camilleri, Duane Burton, Jessica O'Neill, Deborah Eckert, Paula Carlson, Alan R. Zinsmeister

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Obesity is associated with differences in satiety, gastric emptying (GE), gastric volume, and psychological traits. Exenatide, a short-acting glucagon-like peptide 1 (GLP-1) receptor agonist, is associated with variable weight loss. We compared the effects of exenatide, 5 μg, and placebo SQ, twice daily for 30 days on GE of solids and liquids (scintigraphy), satiety (ad libitum buffet meal), satiation (nutrient drink test, maximum tolerated volume [MTV]), and weight loss in 20 participants with documented accelerated GE of solids (T1/2 < 90 min). Exenatide delayed GE of solids (T1/2 [Δ] 86 min relative to placebo, P < 0.001) and reduced calorie intake at buffet meal ([Δ] 129 kcal compared to placebo). Median weight loss was −0.95 kg (IQR −0.7 to −2.1) for exenatide and −0.55 kg (0.3 to −2.1) for placebo (P = 0.23); 80% of exenatide group had documented reduction in weight. In the exenatide treatment group, there was an inverse correlation between gastric emptying T1/2 and MTV (R = −0.548, P = 0.089). The univariate association of weight change with posttreatment MTV was borderline (Rs = 0.43, P = 0.06); in the multiple regression model, posttreatment MTV was associated with weight change (P = 0.047). The effect of the short-acting GLP-1 receptor agonist, exenatide, on GE is associated with the change in food intake, and the latter impacts weight loss in response to exenatide treatment.

Original languageEnglish (US)
Article numbere12610
JournalPhysiological Reports
Volume3
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Gastric Emptying
Obesity
Weight Loss
Placebos
Meals
Satiation
Weights and Measures
exenatide
Radionuclide Imaging
Stomach
Eating
Psychology
Food
Therapeutics

Keywords

  • Glucagon-like peptide 1
  • pharmacogenomics
  • satiation

ASJC Scopus subject areas

  • Physiology (medical)
  • Physiology

Cite this

Exenatide in obesity with accelerated gastric emptying : a randomized, pharmacodynamics study. / Acosta, Andres; Camilleri, Michael; Burton, Duane; O'Neill, Jessica; Eckert, Deborah; Carlson, Paula; Zinsmeister, Alan R.

In: Physiological Reports, Vol. 3, No. 11, e12610, 01.11.2015.

Research output: Contribution to journalArticle

Acosta, Andres ; Camilleri, Michael ; Burton, Duane ; O'Neill, Jessica ; Eckert, Deborah ; Carlson, Paula ; Zinsmeister, Alan R. / Exenatide in obesity with accelerated gastric emptying : a randomized, pharmacodynamics study. In: Physiological Reports. 2015 ; Vol. 3, No. 11.
@article{14d61797772a462ab2d274d8964127b8,
title = "Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study",
abstract = "Obesity is associated with differences in satiety, gastric emptying (GE), gastric volume, and psychological traits. Exenatide, a short-acting glucagon-like peptide 1 (GLP-1) receptor agonist, is associated with variable weight loss. We compared the effects of exenatide, 5 μg, and placebo SQ, twice daily for 30 days on GE of solids and liquids (scintigraphy), satiety (ad libitum buffet meal), satiation (nutrient drink test, maximum tolerated volume [MTV]), and weight loss in 20 participants with documented accelerated GE of solids (T1/2 < 90 min). Exenatide delayed GE of solids (T1/2 [Δ] 86 min relative to placebo, P < 0.001) and reduced calorie intake at buffet meal ([Δ] 129 kcal compared to placebo). Median weight loss was −0.95 kg (IQR −0.7 to −2.1) for exenatide and −0.55 kg (0.3 to −2.1) for placebo (P = 0.23); 80{\%} of exenatide group had documented reduction in weight. In the exenatide treatment group, there was an inverse correlation between gastric emptying T1/2 and MTV (R = −0.548, P = 0.089). The univariate association of weight change with posttreatment MTV was borderline (Rs = 0.43, P = 0.06); in the multiple regression model, posttreatment MTV was associated with weight change (P = 0.047). The effect of the short-acting GLP-1 receptor agonist, exenatide, on GE is associated with the change in food intake, and the latter impacts weight loss in response to exenatide treatment.",
keywords = "Glucagon-like peptide 1, pharmacogenomics, satiation",
author = "Andres Acosta and Michael Camilleri and Duane Burton and Jessica O'Neill and Deborah Eckert and Paula Carlson and Zinsmeister, {Alan R.}",
year = "2015",
month = "11",
day = "1",
doi = "10.14814/phy2.12610",
language = "English (US)",
volume = "3",
journal = "Physiological Reports",
issn = "2051-817X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Exenatide in obesity with accelerated gastric emptying

T2 - a randomized, pharmacodynamics study

AU - Acosta, Andres

AU - Camilleri, Michael

AU - Burton, Duane

AU - O'Neill, Jessica

AU - Eckert, Deborah

AU - Carlson, Paula

AU - Zinsmeister, Alan R.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Obesity is associated with differences in satiety, gastric emptying (GE), gastric volume, and psychological traits. Exenatide, a short-acting glucagon-like peptide 1 (GLP-1) receptor agonist, is associated with variable weight loss. We compared the effects of exenatide, 5 μg, and placebo SQ, twice daily for 30 days on GE of solids and liquids (scintigraphy), satiety (ad libitum buffet meal), satiation (nutrient drink test, maximum tolerated volume [MTV]), and weight loss in 20 participants with documented accelerated GE of solids (T1/2 < 90 min). Exenatide delayed GE of solids (T1/2 [Δ] 86 min relative to placebo, P < 0.001) and reduced calorie intake at buffet meal ([Δ] 129 kcal compared to placebo). Median weight loss was −0.95 kg (IQR −0.7 to −2.1) for exenatide and −0.55 kg (0.3 to −2.1) for placebo (P = 0.23); 80% of exenatide group had documented reduction in weight. In the exenatide treatment group, there was an inverse correlation between gastric emptying T1/2 and MTV (R = −0.548, P = 0.089). The univariate association of weight change with posttreatment MTV was borderline (Rs = 0.43, P = 0.06); in the multiple regression model, posttreatment MTV was associated with weight change (P = 0.047). The effect of the short-acting GLP-1 receptor agonist, exenatide, on GE is associated with the change in food intake, and the latter impacts weight loss in response to exenatide treatment.

AB - Obesity is associated with differences in satiety, gastric emptying (GE), gastric volume, and psychological traits. Exenatide, a short-acting glucagon-like peptide 1 (GLP-1) receptor agonist, is associated with variable weight loss. We compared the effects of exenatide, 5 μg, and placebo SQ, twice daily for 30 days on GE of solids and liquids (scintigraphy), satiety (ad libitum buffet meal), satiation (nutrient drink test, maximum tolerated volume [MTV]), and weight loss in 20 participants with documented accelerated GE of solids (T1/2 < 90 min). Exenatide delayed GE of solids (T1/2 [Δ] 86 min relative to placebo, P < 0.001) and reduced calorie intake at buffet meal ([Δ] 129 kcal compared to placebo). Median weight loss was −0.95 kg (IQR −0.7 to −2.1) for exenatide and −0.55 kg (0.3 to −2.1) for placebo (P = 0.23); 80% of exenatide group had documented reduction in weight. In the exenatide treatment group, there was an inverse correlation between gastric emptying T1/2 and MTV (R = −0.548, P = 0.089). The univariate association of weight change with posttreatment MTV was borderline (Rs = 0.43, P = 0.06); in the multiple regression model, posttreatment MTV was associated with weight change (P = 0.047). The effect of the short-acting GLP-1 receptor agonist, exenatide, on GE is associated with the change in food intake, and the latter impacts weight loss in response to exenatide treatment.

KW - Glucagon-like peptide 1

KW - pharmacogenomics

KW - satiation

UR - http://www.scopus.com/inward/record.url?scp=84977609334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977609334&partnerID=8YFLogxK

U2 - 10.14814/phy2.12610

DO - 10.14814/phy2.12610

M3 - Article

AN - SCOPUS:84977609334

VL - 3

JO - Physiological Reports

JF - Physiological Reports

SN - 2051-817X

IS - 11

M1 - e12610

ER -